Low-dose valproic acid with low-dose gemcitabine augments MHC class I-related chain A/B expression without inducing the release of soluble MHC class I-related chain A/B

TOMOHARU MIYASHITA¹, KENJI MIKI², TAKASHI KAMIGAKI², ISAMU MAKINO¹, HIDEHIRO TAJIMA¹, SHINICHI NAKANUMA¹, HIRONORI HAYASHI¹, HIROYUKI TAKAMURA¹, SACHIO FUSHIDA¹, ALI K. AHMED³, JOHN W. HARMON³ and TETSUO OHTA¹

¹Department of Gastroenterological Surgery, Kanazawa University Hospital, Kanazawa, Ishikawa 920-8641; ²Medinet Medical Institute, MEDINET Co., Ltd., Tokyo 158-0096, Japan; ³Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA

Received April 27, 2016; Accepted June 2, 2017

DOI: 10.3892/ol.2017.6943

Abstract. To improve natural killer group 2 member D (NKG2D)-dependent cytotoxicity, the inhibition of cleavage and release of major histocompatibility complex class I-related chain (MIC) molecules from the tumor surface are required. Valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, is able to induce cell-surface MICA/B on tumor cells. In the present study, the ability of VPA and gemcitabine (GEM) to upregulate MICA/B in pancreatic cancer cells was investigated, resulting in the inhibition of cleavage and release of MIC molecules from the tumor surface. Flow cytometry was used to quantify MICA/B expression in six human pancreatic cancer lines. Functional cytotoxic activity of γδT cells against pancreatic cancer cells treated with VPA and GEM was determined using cytotoxicity assays. At low doses of VPA (0.7 mM) and GEM (0.001 µM), which did not induce tumor growth alterations, the agents individually increased cell-surface MICA/B expression in MICA/B-positive cell lines, but not in the MICA/B-negative cell line. Furthermore, the combination of VPA and GEM synergistically induced cell-surface MICA/B expression. In MICA/B-positive cell lines, the increase in MICA/B expression was dependent on VPA concentration. The combination of low-dose VPA and GEM enhanced the susceptibility of the PANC-1 cell line to γδT cell-mediated tumor cell lysis. It was observed that soluble MIC was released from PANC-1 in the culture supernatant following treatment with GEM. However, the combination of low-dose VPA with low-dose GEM increased MICA/B expression without inducing soluble MIC, resulting in enhanced tumor cell lysis. The results of the present study suggest that the combined administration of low-dose VPA with low-dose GEM has the potential to enhance the therapeutic effects of immunotherapy in pancreatic cancer. Furthermore, it is proposed that the combination acts, in part, by upregulating MICA/B and prevents soluble MIC from being released.

Introduction

Pancreatic ductal adenocarcinoma (PDAC), one of the most lethal of all types of human cancer, is a common cause of cancer mortality in the USA and Japan (1). PDAC is the fourth most common cause of cancer-associated mortality and its incidence is increasing worldwide (2). PDAC displays local invasion and distant metastasis during early disease stages and this leads to an extremely poor prognosis, with an overall survival rate of <5% (2). As such, there is a requirement for novel and more effective treatment strategies. Research has focused on the development of immunomodulatory approaches (3).

Interactions between the immune system and malignant cells play an important role in tumorigenesis (4). Tumors have employed multiple mechanisms of immune evasion. One such mechanism, particularly in high-grade cancer, involves cytotoxic T lymphocyte (CTL) evasion through major histocompatibility complex (MHC) class I downregulation (5). Tumor cells express cell-surface MHC class I chain-related gene A/B (MICA/B), frequently induced under cellular stress. MICA/B function as ligands for natural killer group 2 member D (NKG2D), expressed on cytotoxic innate immune cells, specifically γδT cells and
natural killer (NK) cells (6). Unlike conventional αβT cells, γδT cells recognize antigens in an MHC-unrestricted manner, and may provide a novel immunotherapeutic approach against tumor cells (7,8). Therefore, MICA/B expression in PDAC serve as targets for various effector cells expressing NKG2D.

Histone deacetylase (HDAC) inhibitors, which alter histone acetylation, are also promising anticancer agents (9,10). A number of clinical studies are currently investigating HDAC inhibitors, and certain HDAC inhibitors have already been approved by the US Food and Drug Administration for the treatment of cutaneous T cell lymphoma (11). However, certain HDAC inhibitors are of limited therapeutic use owing to toxic side effects at high doses. Valproic acid (VPA) exhibits anti-tumor effects of HDAC inhibitors and has been demonstrated to exert anticancer effects in various cancer models (12,13). The therapeutic range of VPA is between 0.35 and 0.7 mM (14). A number of studies have demonstrated that VPA stimulates the expression of cell-surface MICA/B in a variety of tumors, enhancing the susceptibility of tumor cells to cell-mediated cytotoxicity (7,15-17).

Gemcitabine (GEM), a nucleoside analogue, is commonly administered as an initial chemotherapy drug for the treatment of pancreatic cancer (18). GEM also induces MICA/B expression on the surface of pancreatic cancer cells (19). In our previous study, it was demonstrated that cell-surface MICA/B expression was upregulated following low-dose GEM treatment, at a concentration not affecting cell growth (20).

However, to the best of our knowledge, the combined effects of VPA and GEM have not yet been investigated. In the present study, the effect of VPA with GEM on the expression of MICA/B was investigated in pancreatic cancer cell lines. It was determined that the cytotoxic efficacy of γδT cells directed at tumors is dependent on the ability of VPA and GEM to prevent tumor immune evasion. This is facilitated by pancreatic cell-surface MICA/B expression without cleavage or release of MIC molecules from the tumor surface.

Materials and methods

Human pancreatic cancer cell lines. Human pancreatic cancer cell lines (PANC-1, BxPC-3, HPAF-II, MIA PaCa-2, Capan-1 and AsPC-1) were purchased from the American Type Culture Collection (Manassas, VA, USA). These cell lines were cultured in RPMI-1640 medium with 10% fetal bovine serum, 10 mM HEPES, 1 mM sodium pyruvate, 1% non-essential amino acid solution, 5×10⁻⁵ M 2-mercaptoethanol, 100 U/ml penicillin and 100 μg/ml streptomycin (all from Thermo Fisher Scientific, Inc., Waltham, MA, USA).

Antibodies and reagents. VPA was obtained from Sigma-Aldrich; Merck KGaA (Darmstadt, Germany). GEM was obtained from Eli Lilly (Indianapolis, IN, USA). Clear Back (human Fc receptor blocking reagent; cat. no. MTG-001), anti-human MICA antibody (dilution, 1:100; cat. no. K0217-3), anti-human MICB antibody (dilution, 1:100; cat. no. K0220-3) and anti-mouse immunoglobulin (Ig)G-fluorescein isothiocyanate (FITC) secondary antibody (dilution, 1:160; cat. no. 238) were obtained from MBL International Co. (Woburn, MA, USA). Phycocerythrin (PE)-conjugated anti-human MICA/B antibody (dilution, 1:20; cat. no. 320906), mouse IgG2a κ isotype control (dilution, 1:20; cat. no. 400211), FITC-conjugated anti-human leukocyte antigen (HLA)-A, -B and -C antibodies (dilution, 1:50; cat. no. 311403), and mouse IgG2a κ isotype control (dilution, 1:50; cat. no. 400207) were purchased from BioLegend, Inc. (San Diego, CA, USA). FITC-conjugated anti-human Vγ9 antibody (dilution, 1:5; cat. no. IM1463) and PE-cyanin 5.1-conjugated anti-human cluster of differentiation (CD) 3 antibody (dilution, 1:10; cat. no. A07749) were acquired from Beckman Coulter, Inc. (Brea, CA, USA). ALys-203, containing 1,000 IU/ml interleukin-2 (IL-2), was purchased from Cell Science & Technology Institute (Sendai, Japan). Zoledronate (Zometa®) was acquired from Novartis International AG (Basel, Switzerland). Calcein-acetoxyethyl ester (AM) was obtained from Dojindo Molecular Technologies, Inc. (Kumamoto, Japan). Anti-human NKG2D monoclonal antibody (mAb) (catalog No. MAB139) was purchased from R&D Systems, Inc. (Minneapolis, MN, USA). WST-1 was acquired from Roche Diagnostics (Basel, Switzerland).

Expansion of γδT cells. γδT cells, obtained from healthy volunteers (n=3) following provision of written informed consent, were expanded from peripheral blood mononuclear cells (PBMCs), as described previously (21). PBMCs were cultured with ALyS-203, containing 1,000 IU/ml IL-2 and 5 μM zoledronate. Cell density was maintained at (0.5-2)x10⁶ cells/ml. Additional PBMCs were cultured with ALyS-203, containing 1,000 IU/ml IL-2, in the absence of zoledronate. On day 12, cells were harvested, and the frequency of γδT cells, identified by subsets CD3γδ and Vγ9, were analyzed using flow cytometry. These cells were used as effector cells (E) in the cytotoxicity assay.

WST-1 assay. Human pancreatic cancer cell lines were treated with various concentrations of VPA between 0 and 5 mM. After 48 h, the viability of each cell line was analyzed using a WST-1 assay, as described previously (22).

Immunofluorescence staining and flow cytometry. Human pancreatic cancer cell lines were cultured in a 10 mm tissue culture dish for 24 h. Each cell line was subsequently treated with VPA alone, or VPA with GEM, for 48 h. Prior to staining with fluorescent antibodies, the Fc receptor was blocked with Clear Back. The expression of MICA/B, and HLA-A, -B and -C on each pancreatic cancer cell line was determined by immunofluorescence staining with PE-conjugated anti-MICA/B antibody and FITC-conjugated HLA-A, -B and -C antibodies. To evaluate MICA/B expression by each pancreatic cancer cell line, cells were first stained with anti-MICA or -MICB antibody and subsequently stained with anti-mouse IgG-FITC secondary antibody. Fluorescence was analyzed using an EPICS XL flow cytometer (Beckman Coulter, Inc., Brea, CA, USA).

Cytotoxicity assay. γδT cell cytotoxicity against human pancreatic cancer cell lines were evaluated using a calcein-AM release assay. Pancreatic cancer cell lines were treated with 0.7 mM VPA, 0.001 μM GEM or a combination of 0.7 mM VPA and 0.001 μM GEM for 48 h. Subsequently, pancreatic
cancer cell lines were labeled with 5 µM calcein-AM for 30 min at 37°C. Following washing three times with medium, calcein-AM-labeled cells were used as target cells (T). As effector cells (E), γδT cells were expanded from PBMCs as aforementioned. To evaluate γδT cell cytotoxicity, effector cells were co-cultured with target cells at various E/T ratios (1, 5 and 25) at 37°C for 3 h. In blocking experiments, anti-NKG2D mAb was added to γδT cell suspension at 10 µg/ml, 30 min prior to co-culturing with target cells. In order to measure the spontaneous release and maximum release of fluorescence intensity from target cells, medium or 6% Triton X-100 was added to target cells. Fluorescence intensity was measured with Terascan VPC (Minerva Tech, Tokyo, Japan) prior to and following culture. The percentage of target cells killed by γδT cells was calculated using Calct-96l software (Minerva Tech, Tokyo, Japan). Triplicate experiments were performed.

ELISA. Following treatment of human pancreatic cancer cell lines with 0.7 mM VPA, GEM (0.001, 0.1, 10 µM) or a combination of 0.7 mM VPA and GEM (0.001, 0.1, 10 µM) for 48 h, in order to detect soluble MICA and MICB in the culture supernatant, sandwich ELISA. An Ab-Match Universal kit (cat. no. 5310), Ab-Match ASSEMBLY Human MICA kit (cat. no. 5330) and Ab-Match Assembly Human MICB kit (cat. no. 5331, all MBL International Co., Woburn, MA, USA) were used according to manufacturers’ protocol.

Statistical analysis. Differences were analyzed for significance using Student’s t-test, Mann-Whitney rank sum test, χ² test or log-rank test, as appropriate. Data management and statistical analysis were performed using SPSS software (version 15; SPSS, Inc., Chicago, IL, USA). P<0.05 was considered to indicate a statistically significant difference.

Results

MICA/B, and HLA-A, -B and -C expression by pancreatic cell lines. MICA/B, and HLA-A, -B, and -C expression by six pancreatic cell lines were analyzed using flow cytometry. As demonstrated in our previous study, the cell-surface MICA/B expression was detected in four pancreatic cell lines (PANC-1, BxPC-3, MIA PaCa-2 and Capan-1), but not in the remaining cell lines (HPAF-II, AsPC-1) (20). The HPAF-II cell line only expressed MICA but not MICB, and AsPC-1 expressed neither MICA nor MICB. Cell-surface expression of HLA-A, -B and -C was detected in all pancreatic cell lines investigated.

VPA concentration affects pancreatic cancer cell growth. To determine whether the concentration of VPA had an effect on the viability of each pancreatic cancer cell line, cell lines were analyzed following treatment with various concentrations of VPA for 48 h using a WST-1 assay. As presented in Fig. 1, VPA doses <1 mM did not affect the viability of PANC-1, BxPC-3, MIA PaCa-2 and Capan-1 cells. However, cell viability decreased with 1 mM VPA treatment in BxPC-3 and HPAF-II cell lines. Following treatment with 5 mM VPA, cell viability decreased in all pancreatic cancer cell lines. This result indicated that VPA at a concentration of 5 mM has an antineoplastic effect.

Effect of MICA/B, and HLA-A, -B and -C expression on pancreatic cancer cell lines following VPA treatment.
MICA/B expression was quantified on pancreatic cancer cell lines following treatment with various concentrations of VPA. As presented in Fig. 2A, it was determined that VPA treatment resulted in an alteration in MICA/B expression in each pancreatic cancer cell line. MICA/B expression was increased in VPA-treated MICA/B-positive cell lines PANC-1, BxPC-3, HPAF-II, MIA PaCa-2 and Capan-1, but not in the MICA/B-negative cell line AsPC-1. In MICA/B-positive cell lines, the increase in cell-surface MICA/B expression was dependent on VPA concentration. Following 5 mM VPA treatment, cell-surface MICA/B expression increased in PANC-1 and BxPC-3 cells, and markedly in MIA PaCa-2 cells, but not in AsPC-1 cells (Fig. 2B). This result demonstrates that cell-surface MICA/B expression may be increased with high doses of VPA in MICA/B-positive pancreatic cancer cell lines. As presented in Fig. 2C and D, treatment with various concentrations of VPA was able to alter HLA-A, -B and -C expression levels, but not to the level observed with MICA/B. In PANC-1 and Capan-1 cells, HLA-A, -B and -C expression was increased following VPA treatment. However, HLA-A, -B and -C expression was not observed to be increased in other pancreatic cancer cell lines.

**MICA/B expression following treatment with low-dose VPA and low-dose GEM.** In an effort to increase MICA/B expression effectively on the cell surface, MICA/B expression by pancreatic cancer cell lines was investigated following treatment with low-dose VPA combined with low-dose GEM.

Fig. 3A indicates that the combination of 0.7 mM VPA and 0.001 mM GEM treatment resulted in an alteration in the MICA/B expression level in each pancreatic cancer cell line. VPA at 0.7 mM increased MICA/B expression on the cell surface of the MICA/B-positive pancreatic cancer cell lines PANC-1, BxPC-3, HPAF-II, MIA PaCa-2 and Capan-1. Likewise, MICA/B expression on all MICA/B-positive pancreatic cancer cell lines, except BxPC-3, was increased following low-dose GEM treatment. When treated with a combination of VPA and GEM, MICA/B expression was increased synergistically in pancreatic cancer cell lines to a level greater than that with VPA or GEM treatment, individually. Conversely,
MICA/B expression was not increased in the MICA/B-negative cell line AsPC-1 using VPA, GEM or a combination of VPA and GEM treatment (Fig. 3B).

As presented in Fig. 3C and D, the administration of low-dose VPA and low-dose GEM resulted in an alteration in the HLA-A, -B and -C expression level in each pancreatic cancer cell line. In all pancreatic cancer cell lines, except HPAF-II, HLA-A, -B and -C expression was slightly increased with a combination of VPA and GEM treatment.

Cytotoxic activity of γδT cells against pancreatic cancer cell lines treated with low-dose VPA and low-dose GEM combination treatment. To assess whether NKG2D-dependent cytotoxic activity was enhanced due to increased MICA/B expression on target cells, γδT cell cytotoxicity against pancreatic cancer cell lines treated with 0.7 mM VPA, 0.001 µM GEM or a combination of VPA and GEM was evaluated. As presented in Fig. 4, cytotoxic activity of γδT cells against PANC-1 was observed. In addition, this cytotoxic activity was blocked using the anti-NKG2D antibody. γδT cells killed PANC-1 cells, which was dependent on the interaction of NKG2D with MICA/B. The cytotoxic activity of γδT cells was enhanced with VPA or GEM, when administered individually. However, when target cells were treated with a low-dose combination of VPA and GEM, there was enhancement of γδT cell cytotoxicity against tumor cells. In the MICA/B-negative cell line AsPC-1, the cytotoxic activity of γδT cells was not detected with or without VPA, GEM or a combination of VPA and GEM (Fig. 4).

Release of soluble MICA/B from pancreatic cancer cell lines treated with GEM or VPA+GEM. The results of the present study demonstrate that low-dose VPA (0.7 mM) with a cytostatic concentration of GEM (0.001 µM) most effectively increased MICA/B expression in PANC-1 cells. To examine the value of the combination of VPA with GEM, the presence of soluble MICA/B in the culture supernatant was determined using ELISA. This would indicate that MICA/B was released.
Figure 4. Effect of VPA, GEM and the combination of VPA with GEM on the susceptibility of PANC-1 and AsPC-1 cells to γδT cell-mediated cytotoxicity. The cytotoxicity of γδT cells was enhanced following treatment with VPA and GEM, when administered separately. Furthermore, the cytotoxicity was enhanced additionally following combination treatment of VPA and GEM in PANC-1 cells. However, cytotoxicity was not enhanced with either treatment in AsPC-1 cells. VPA, valproic acid; GEM, gemcitabine.

Figure 5. Effect of treatment with GEM or combination of VPA and GEM on the production of soluble MICA/B. (A) In PANC-1 cells, soluble MICA/B remained at high concentrations in the culture supernatant when treated with various doses of GEM, whereas soluble MICA/B decreased following a combination treatment of low-dose VPA with low-dose GEM. (B) In AsPC-1 cells, soluble MICA/B was released slightly into the culture supernatant following treatment with various doses of GEM and the combination treatment of VPA with GEM. *P<0.05; n.s., not significant; GEM, gemcitabine; VPA, valproic acid; MICA/B, major histocompatibility complex class 1-related chain A/B.
from pancreatic cancer cell lines treated with GEM, or with a combination of VPA and GEM.

In PANC-1 cells (Fig. 5), a high concentration of soluble MICA/B was detected in the culture supernatant. When PANC-1 cells were treated with various doses of GEM, soluble MICA/B remained at high concentrations in the culture supernatant. Soluble MICA/B decreased when treated with low-dose GEM combined with low-dose VPA.

Soluble MICA/B was released, to a minimal degree, in the culture supernatant of AsPC-1 (Fig. 5). Soluble MICB was detected, despite a lack of cell-surface expression, in this cell line.

Discussion

In humans, MHC-associated molecules termed MICA/B, are well known as NKG2D ligands. Rarely expressed in healthy cells, MICA/B are frequently expressed in epithelial tumor cells, and in cells under stress. These cells under stress include those undergoing heat shock, viral infection and DNA damage (23,24). The immunoreceptor that recognizes MICA/B, NKG2D, is expressed by γδT and NK cells. Therefore, it may be possible that NKG2D-dependent cytotoxic activity is enhanced with increased MICA/B expression.

VPA has been used clinically to treat migraines and as a mood stabilizer. The therapeutic dose of VPA ranges between 15 and 60 mg/kg/day, and results in a maximum plasma concentrations of 130 μg/ml (0.9 mM) (25). VPA levels in epilepsy patients are typically <0.7 mM (26). VPA has been found to act as an HDAC inhibitor (27). Concentrations of VPA for histone acetylation range between 0.25 and 5 mM. In addition, it has been reported that HDAC inhibitors display antineoplastic activity (28,29) and induce NKG2D ligands, such as MICA/B and UL16-binding proteins, on tumor cells (15,30). Furthermore, in vivo and in vitro studies have demonstrated that VPA enhances NK cell-mediated lysis and upregulates MICA/B expression in pancreatic cancer through the activation of the phosphoinositide 3-kinase/protein kinase B signaling pathway, which has important implications in the pancreatic cancer stroma microenvironment (31,32).

The results of the present study indicate that increased cell-surface MICA/B expression on pancreatic cancer cell lines was dependent on the VPA concentration. Furthermore, when pancreatic cancer cell lines were treated with 5 mM VPA treatment, the viability of those cell lines were decreased and cell-surface MICA/B expression was increased markedly. Therefore, it may be possible that high doses of VPA treatment combined with immunotherapy are able to induce a marked antitumor response. This is due to the enhanced NKG2D-dependent cytotoxicity of immune cells and the antineoplastic effect of VPA. However, because the maximum plasma concentration is 0.9 mM following VPA administration (25), it is necessary to induce the antineoplastic effect of VPA in low doses. Low-dose VPA, <1 mM, was unable to kill pancreatic cancer cell lines with its antineoplastic activity and slightly increased MICA/B expression. Therefore, it was attempted to increase MICA/B expression effectively with low-dose VPA combined with low-dose GEM, as another immunomodulatory reagent.

GEM is a chemotherapeutic agent that has an immunomodulatory effect. It functions by upregulating the cell-surface MICA/B expression for various types of cancer. Results of our previous study indicated that MICA/B expression on the cell surface was increased effectively at low doses of GEM, with no effect on cell viability (20). The results of the present study indicate that the combination of low-dose VPA with low-dose GEM is able to increase cell-surface MICA/B expression on pancreatic cancer cell lines. In addition, NKG2D-dependent cytotoxicity of γδT cells was enhanced with the increase of MICA/B expression by pancreatic cancer cell lines. When PANC-1 was treated with a combination of VPA and GEM, MICA/B expression on the cell surface was increased 2.5-fold in comparison with those untreated in the same cell line.

γδT cells are able to recognize and respond to various stress-induced antigens, thereby developing innate immunity (33). They also exhibit potent effector functions, including cytotoxic activity, and the secretion of cytokines/chemokines. The majority of γδT cells in peripheral blood possess the Vγ9Vδ2 T cell receptor. The cytotoxicity of these γδT cells is mediated by perforin-granzyme, CD95/CD95 ligands, tumor necrosis factor (TNF)/TNF receptors and TNF-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor (TRAILR) systems (34). It may be possible that the cytotoxic activity of γδT cells is enhanced through the activation of a number of effector functions. It was reported that HDAC inhibitors were able to increase TRAIL sensitivity in target tumor cells (35). In the present study, it may be possible that cytotoxicity was enhanced by a combination of effectors functions, NKG2D-NKG2D ligand interactions and TRAIL/TRAILR sensitivity following the treatment combination of VPA and GEM. In TRAIL-resistant pancreatic cancer cell lines, it was shown that the inhibition of anti-apoptotic B-cell lymphoma extra large (Bel-XL) protein promoted apoptosis with TRAIL (36). Therefore, the addition of another agent that is able to inhibit Bel-XL expression may enhance the cytotoxic activity of γδT cells, when TRAIL-resistant tumor cells are treated with VPA and GEM.

A number of clinical studies have emphasized the therapeutic benefits of immunotherapy in combination with chemotherapy (37,38). Therefore, to improve therapeutic benefits, it may be required to combine another chemotherapeutic agent with immunomodulatory agents. One effective approach to improve the therapeutic efficacy of immunotherapy is to prevent immune evasion mechanisms by tumor cells.

In a previous study, it was demonstrated that the release of MIC molecules on the cell surface constitutes an immune evasion mechanism in tumor cells (39). Soluble MICA/B, cleaved on tumor cells, downregulate the cell-surface expression of NKG2D on T cells. This induces the functional impairment of antitumor immune effector cells. As such, proteolytic cleavage may decrease the expression of NKG2D ligands on tumor cell surfaces and contribute to tumor evasion from immunosurveillance. Soluble MIC is perceived as a stress-inducing ligand (TRAIL)/TRAIL receptor (TRAILR) system,

In the tumor microenvironment, soluble MICA induces the internalization and lysosomal degradation
of the NKG2D receptor in CD8+ T and NK cells (41). It may be possible that the inhibition of these proteases enhances NKG2D-dependent cytotoxicity. This is due to an increase in MICA/B expression on target cell surfaces, and decrease in soluble MICA/B induction through the prevention of MICA/B cleavage. In our previous study, there was a problem with cleavage and release of MIC molecules from the tumor surface, which resulted in tumors evading immunosurveillance (20). In the present study, soluble MICA/B expression decreased with the combination of low-dose VPA and low-dose GEM, despite increased expression in PANC-1 cells. On the surface of osteosarcoma cells, VPA has been reported to be associated with the downregulation of ADAM10, which cleaves MICA/B (42). In addition, VPA downregulates the activity of matrix metalloproteinase which produce soluble MICA/B (43,44).

In order to prevent the tumor cell immune evasion mechanism and implement effective therapeutic efficacy in immunotherapy, it may be essential to combine a number of immunomodulatory agents and enhance effector functions on immune cells.

The results of the present study indicate that the combined administration of low-dose VPA and low-dose GEM is valuable in enhancing the therapeutic efficacy of immunotherapy by upregulating MICA/B without inducing soluble MIF from being released in pancreatic cancer.

Acknowledgements

The present study was supported by the Japan Society for the Promotion of Science (KAKENHI grant no. 25462106).

References

1. Lowenfels AB and Maisonneuve P: Epidemiology and prevention of pancreatic cancer. Jpn J Clin Oncol 34: 238-244, 2004.
2. Siegel R, Ward E, Brawley O and Jemal A: Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61: 212-236, 2011.
3. Jaffee EM, Hruban RH, Biedrzycki B, Laheur S, Scheper R, Gromisz M, Coleman J, Grochow L, Donehower RC, et al.: Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: A phase I trial of safety and immune activation. J Clin Oncol 19: 145-156, 2001.
4. Igney FH and Krammer PH: Immune escape of tumors: Apoptosis resistance and tumor counterattack. J Leukoc Biol 71: 907-920, 2002.
5. Bernal M, Garrido P, Jiménez P, Jimenez P, 907-920, 2002.
6. Suzuki T, Terao S, Achiwa Y, Naoe M, Yamamoto S, Okamura H and Gotoh A: The antitumour effect of gamma delta T cells is enhanced by valproic acid-induced up-regulation of NKG2D ligands. Anticancer Res 30: 4509-4513, 2010.
7. Groh V, Rhinehart R, Secrist H, Bauer S, Grabstein KH and Spies T: Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc Natl Acad Sci USA 96: 6879-6884, 1999.
8. Glozak MA and Seto E: Histone deacetylases and cancer. Oncogene 26: 5420-5432, 2007.
9. Lane AA and Chabner BA: Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 27: 5459-5468, 2009.
10. Mann RS, Johnson JR, Cohen MH, Justice R and Pazdur R: FDA approval summary: Vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 12: 1247-1252, 2007.
11. Yang Y, Fukushima S, Harada S, Kinoshita J, Makino I, Oyama Y, Tajima H, Fujita H, Takamura H, Ninomiya I, et al.: Effects of valproic acid on the cell cycle and apoptosis through acetylation of histone and tubulin in a murine gastric cancer cell line. J Exp Clin Cancer Res 29: 149, 2010.
12. Shoji M, Ninomiya I, Makino I, Kinoshita J, Nakamura K, Oyama K, Nakagawara H, Fujita H, Tajima H, Takamura H, et al.: Valproic acid, a histone deacetylase inhibitor, enhances radiosensitivity in esophageal squamous cell carcinoma. Int J Oncol 40: 2140-2146, 2012.
13. Franssen EJ, van Essen GG, Portman AT, de Jong J, Go G, Stegeman CA and Uges DR: Valproic acid toxicokinetics: Serial hemodialysis and hemoperfusion. Ther Drug Monit 21: 289-292, 1999.
14. Armeanu S, Bitzer M, Lauer UM, Venturelli S, Pathil A, Krusch M, Kaiser S, Jobst J, Smirnow I, Wagner A, et al.: Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res 65: 6321-6329, 2005.
15. Poggi A, Catelli S, Garuti A, Pierri I, Gobbi M and Zocchi MR: Effective in vivo induction of NKG2D ligands in acute myeloid leukemias by all-trans-retinoic acid or sodium valproate. Leukemia 23: 641-648, 2009.
16. Yamanegi K, Yamane J, Kobayashi K, Kato-Kogoe N, Oyama H, Nakasho K, Yamada N, Hata M, Nishitoh T, Fukunaga S, et al.: Sodium valproate, a histone deacetylase inhibitor, decreased expression of cell-surface NKG2D ligands, MICA/B, without increasing their soluble forms to enhance susceptibility of human osteosarcoma cells to NK cell-mediated cytotoxicity. Oncol Rep 24: 1621-1627, 2010.
17. Galan P: Pancreatic cancer. N Engl J Med 362: 1605-1617, 2010.
18. Xu X, Rao GS, Groh V, Spies T, Gattuso P, Kaufman HL, Plate J and Prinz RA: Major histocompatibility complex class I-related chain A/B (MICA/B) expression in tumor tissue and serum of pancreatic cancer: Role of uric acid accumulation in gemcitabine-induced MICA/B expression. BMC Cancer 11; 194, 2011.
19. Miyashita T, Miki K, Kamigaki T, Makino I, Nakagawara H, Tajima H, Takamura H, Kitagawa H, Fushida S, Ahmed AK, et al.: Low-dose gemcitabine induces major histocompatibility complex class I-related chain A/B expression and enhances an antitumor innate immune response in pancreatic cancer. Clin Exp Med 17: 19-31, 2017.
20. Kondo M, Izumi T, Fujieda N, Kondo A, Morishita T, Matsushita H and Kakimi K: Expansion of human peripheral blood γδ T cells using zoledronate. J Vis Exp: pii:31822, 2011.
21. Tatsumi T, Takehara T, Yamaguchi S, Sasakawa A, Sakamori R, Ohkawa K, Kohga K, Uemura A and Hayashi N: Infranepatic delivery of alpha-galactosylceramide-pulsed dendritic cells suppresses liver tumor. Hepatology 45: 22-30, 2007.
22. Lu J, Aggarwal R, Kanji S, Das M, Joseph M, Pompili V and Das H: Human ovarian tumor cells escape γδ T cell recognition partly by downregulated surface expression of MICA and limiting cell cycle related molecules. PLoS One 6: e25348, 2011.
23. Wu J, Groh V and Spies T: Cell antigen receptor engagement and specificity in the recognition of stress-inducible MHC class I-related chains by human epithelial gamma delta T cells. J Immunol 169: 1236-1240, 2002.
24. Marchion D and Münster P: Development of histone deacetylase inhibitors for cancer treatment. Expert Rev Anticancer Ther 7: 583-598, 2007.
25. Catalano MG, Fortunati N, Pugliese M, Costantino L, Poli R, Bosco O and Boccutti G: Valproic acid induces apoptosis and cell cycle arrest in poorly differentiated acute myeloid cancer cells. J Clin Oncol 20: 1383-1389, 2005.
26. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA and Klein PS: Histone deacetylation is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 276: 36734-36741, 2001.
27. Blaheta RA and Cinatl Jr: Anti-tumor mechanisms of valproate: A novel role for an old drug. Med Rev 22: 492-511, 2002.
28. Göttlicher M, Minucci S, Zhu P, Krämer OH, Schimpf A, Giavara S, Steeman JP, Lo Coco F, Nervi C, Pellicci PG and Heinzel T: Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20: 6969-6978, 2001.
29. Yang F, Shao Y, Yang F, Liu M, Huang J, Zhu K, Guo C, Luo J, Li W, Yang B, et al.: Valproic acid upregulates NKG2D ligand expression and enhances susceptibility of human renal carcinoma cells to NK cell-mediated cytotoxicity. Arch Med Sci 9: 323-331, 2013.
31. Shi P, Yin T, Zhou F, Cui P, Gou S and Wang C: Valproic acid sensitizes pancreatic cancer cells to natural killer cell-mediated lysis by upregulating MICA and MICB via the PI3K/Akt signaling pathway. BMC Cancer 14: 370, 2014.

32. Takikawa T, Masamune A, Hamada S, Nakano E, Yoshida N and Shimosegawa T: miR-210 regulates the interaction between pancreatic cancer cells and stellate cells. Biochem Biophys Res Commun 437: 433-439, 2013.

33. Bonneville M, O’Brien RL and Born WK: Gammadelta T cell effector functions: A blend of innate programming and acquired plasticity. Nat Rev Immunol 10: 467-478, 2010.

34. Todaro M, Meraviglia S, Caccamo N, Stassi G and Dieli F: Combining conventional chemotherapy and γδ T cell-based immunotherapy to target cancer-initiating cells. Oncoimmunology 2: e25821, 2013.

35. Schüler S, Fritsche P, Diersch S, Arlt A, Schmid RM, Saur D and Schneider G: HDAC2 attenuates TRAIL-induced apoptosis of pancreatic cancer cells. Mol Cancer 9: 80, 2010.

36. Bai J, Sui J, Demirjian A, Vollmer CM Jr, Marasco W and Callery MP: Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: Tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro. Cancer Res 65: 2344-2352, 2005.

37. Laheru D, Lutz E, Burke J, Biedrzycki B, Solt S, Onners B, Tartakovskiy I, Nemunaitis J, Le D, Sugar E, et al: Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: A pilot study of safety, feasibility, and immune activation. Clin Cancer Res 14: 1455-1463, 2008.

38. Chen G and Emens LA: Chemoimmunotherapy: Reengineering tumor immunity. Cancer Immunol Immunother 62: 203-216, 2013.

39. Salih HR, Rammensee HG and Steinle A: Cutting edge: Down-regulation of MICA on human tumors by proteolytic shedding. J Immunol 169: 4098-4102, 2002.

40. Chitadze G, Lettau M, Bhat J, Wesch D, Steinle A, Fürst D, Mytilineos J, Kalthoff H, Janssen O, Oberg HH and Kabelitz D: Shedding of endogenous MHC class I-related chain molecules A and B from different human tumor entities: Heterogeneous involvement of the ‘α disintegrin and metalloproteases’ 10 and 17. Int J Cancer 133: 1557-1566, 2013.

41. Jinushi M, Takehara T, Tatsumi T, Hiramatsu N, Sakamori R, Yamaguchi S and Hayashi N: Impairment of natural killer cell and dendritic cell functions by the soluble form of MHC class I-related chain A in advanced human hepatocellular carcinomas. J Hepatol 43: 1013-1020, 2005.

42. Yamanegi K, Yamane J, Kobayashi K, Ohyama H, Nakasho K, Yamada N, Hata M, Futunaga S, Futani H, Okamura H and Terada N: Downregulation of matrix metalloproteinase-9 mRNA by valproic acid plays a role in inhibiting the shedding of MHC class I-related molecules A and B on the surface of human osteosarcoma cells. Oncol Rep 28: 1585-1590, 2012.

43. Yamanegi K, Yamane J, Kobayashi K, Kato-Kogoe N, Ohyama H, Nakasho K, Yamada N, Hata M, Futunaga S, Futani H, et al: Valproic acid cooperates with hydralazine to augment the susceptibility of human osteosarcoma cells to Fas- and NK cell-mediated cell death. Int J Oncol 41: 83-91, 2012.

44. Lee KH, Choi EY, Kim MK, Kim KO, Jang BI, Kim SW, Kim SW, Song SK and Kim JR: Inhibition of histone deacetylase activity down-regulates urokinase plasminogen activator and matrix metalloproteinase-9 expression in gastric cancer. Mol Cell Biochem 343: 163-171, 2010.